LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 20

Search options

  1. Article ; Online: Management of hypertension and dyslipidemia in Mexico: Evidence, gaps, and approach.

    Morales-Villegas, Enrique C / Yarleque, Carlos / Almeida, María L

    Archivos de cardiologia de Mexico

    2023  Volume 93, Issue 1, Page(s) 77–87

    Abstract: Hypertension and dyslipidemia are key risk factors for cardiovascular disorders and mortality worldwide. To understand the local health system challenges faced in the management of the two conditions, a semi-systematic approach was adopted for ... ...

    Abstract Hypertension and dyslipidemia are key risk factors for cardiovascular disorders and mortality worldwide. To understand the local health system challenges faced in the management of the two conditions, a semi-systematic approach was adopted for quantifying stages of the journey of care of adult Mexican patients, namely, awareness, screening, diagnosis, treatment, adherence, and control. A structured literature search was conducted for articles published in English from 2010 to 2019 in EMBASE and MEDLINE databases. The articles restricted to patient subgroups, or not having national representativeness, thesis abstracts, letters to the editor, editorials, or case studies were excluded. In addition, an unstructured unrestricted literature search was conducted, on websites of Incidence and Prevalence Database, World Health Organization, Country's Ministry of Health, and Google. Last search was run on 28 August 2020 for Hypertension and 12 November 2019 for Dyslipidemia. Weighted or simple means were calculated for the pooled data. Seven articles of 647 retrievals for hypertension and 11 articles of 1265 retrievals for dyslipidemia were included in the review. The prevalence of hypertension was estimated to be 24.1%, while 59.9% of patients had awareness, 97.5% underwent screening, 18.4% had diagnosis, 50% received treatment, 50% were adherent to treatment, and 49.9% had disease control. Prevalence of dyslipidemia was estimated as 36.7%, while 8.6% of patients had awareness, 48.1% underwent screening, 28% had diagnosis, 68.9% received treatment, 50% were adherent to treatment, and 30% had disease control. The study suggested that addressing the synergistic effect of hypertension and dyslipidemia could reduce cardiovascular risk associated with these conditions.
    MeSH term(s) Adult ; Humans ; Mexico ; Hypertension/epidemiology ; Hypertension/therapy ; Hypertension/diagnosis ; Risk Factors ; Cardiovascular Diseases ; Dyslipidemias/epidemiology ; Dyslipidemias/therapy ; Dyslipidemias/diagnosis
    Language English
    Publishing date 2023-02-02
    Publishing country Mexico
    Document type Journal Article
    ZDB-ID 2059019-2
    ISSN 1665-1731 ; 1665-1731
    ISSN (online) 1665-1731
    ISSN 1665-1731
    DOI 10.24875/ACM.21000330
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: A cross-sectional study on the prevalence of cardiovascular disease in elderly patients with long-term type 2 diabetes mellitus mainly attended in private clinics in Mexico. The CAPTURE study.

    Arenas-León, José L / Morales-Villegas, Enrique C / Cardona-Muñoz, Ernesto G / Alcocer-Gamba, Marco A / Ramirez-Contreras, Juan P / Contreras-Sandoval, Aleida Y / González-Galvez, Guillermo

    Diabetology & metabolic syndrome

    2023  Volume 15, Issue 1, Page(s) 258

    Abstract: Background: To estimate the contemporary prevalence of established cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) in Mexico.: Methods: CAPTURE was a multinational, non-interventional, cross-sectional study across 13 countries from ... ...

    Abstract Background: To estimate the contemporary prevalence of established cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) in Mexico.
    Methods: CAPTURE was a multinational, non-interventional, cross-sectional study across 13 countries from five continents. Standardized demographic and clinical data were collected from adults with T2D attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data from Mexico are analyzed in this study.
    Results: Of the 9,823 patients included in the CAPTURE study, 820 (8.3%) participants were from Mexico, mainly attended in private centers (29.3% in 6 specialized diabetes treatment centers and 70.7% in 26 primary care centers). The median age was 63.0 years, 52.6% were women, the duration of diabetes was 11.8 years and the average HbA1c 7.5%. The weighted prevalence [95% CI] of CVD and atherosclerotic CVD was 36.9% [34.1-39.6] and 29.5% [26.7-32.3], respectively. Additionally, the prevalence of coronary heart disease, heart failure, peripheral arterial disease and cerebrovascular disease was 23.1% [20.6-25-7], 8.4% [6.8-10.0], 5.0% [3.5-6.5] and 3.9% [2.6-5.2], respectively. Glucose lowering drugs were used in 88.5% of patients, being metformin the most commonly drug used (79.4%), followed by sulfonylureas (26.3%). SGLT-2 inhibitors and GLP1 receptor agonists were used in 15.5% and 3.9%, respectively.
    Conclusions: In Mexico, nearly four out of ten patients with T2D mainly attended in private centers have CVD, particularly atherosclerotic CVD. Most patients were not taking glucose lowering drugs with proven CV benefit.
    Language English
    Publishing date 2023-12-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2518786-7
    ISSN 1758-5996
    ISSN 1758-5996
    DOI 10.1186/s13098-023-01231-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins.

    Morales-Villegas, Enrique C / Di Sciascio, Germano / Briguori, Carlo

    International journal of hypertension

    2011  Volume 2011, Page(s) 904742

    Abstract: Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the ... ...

    Abstract Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the decrease of LDL-cholesterol, the reduction of inflammation biomarkers and even the atheroregresion, as surrogate effects to the mechanisms of action of statins would be irrelevant if not accompanied by a significant decrease in the incidence of cardiovascular events. Statins like no other pharmacological group have proven to reduce the incidence of cardiovascular events and prolong life in any clinical scenario. This article review the basic and clinical evidence that support a new indication for HMG-CoA reductase inhibitors "pharmacological myocardial preconditioning before anticipated ischemia" or hyperacute use of statins in subjects with any coronary syndrome eligible for elective, semi-urgent or primary percutaneous coronary intervention: ARMYDA-Original, NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, Korean-STEMI trials.
    Language English
    Publishing date 2011-03-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573167-1
    ISSN 2090-0392 ; 2090-0392
    ISSN (online) 2090-0392
    ISSN 2090-0392
    DOI 10.4061/2011/904742
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Recuperando la función endotelial

    Alfonso Bryce Moncloa / Enrique C Morales-Villegas / Juan Urquiaga Calderón / Cesar Larrauri-Vigna

    Anales de la Facultad de Medicina, Vol 75, Iss 4, Pp 367-

    2014  Volume 374

    Abstract: La enfermedad ateroesclerótica comienza a temprana edad. La presencia de factores de riesgo, como la hipertensión arterial, tabaquismo, dislipidemia y diabetes mellitus, a lo que hoy se suman la obesidad y el síndrome metabólico, originan desde el inicio ...

    Abstract La enfermedad ateroesclerótica comienza a temprana edad. La presencia de factores de riesgo, como la hipertensión arterial, tabaquismo, dislipidemia y diabetes mellitus, a lo que hoy se suman la obesidad y el síndrome metabólico, originan desde el inicio disfunción endotelial, incremento del estrés oxidativo e inflamación, con aparición temprana de células espumosas, estrías grasas y placas de ateroma. Placas que en algunos de los casos son consideradas vulnerables, con un riesgo de sufrir erosión y rotura, el fenómeno aterotrombótico y un evento vascular agudo, como el síndrome coronario agudo y el accidente cerebrovascular. Al manejar y tratar los factores de riesgo cardiovasculares, síndrome metabólico, marcadores precoces del riesgo cardiovascular, se podría enlentecer o retardar el envejecimiento (injuria endotelial) de los órganos blanco, probablemente sin reducción de la mortalidad, pero logrando tres enfoques fundamentales con la detección temprana de la aterotrombosis subclínica: prevenir eventos cardiovasculares, brindar protección de los órganos blanco y mejorar la calidad de vida.
    Keywords Disfunción endotelial ; ateroesclerosis coronaria ; enfermedad coronaria ; Medicine ; R ; Medicine (General) ; R5-920
    Language Spanish
    Publishing date 2014-10-01T00:00:00Z
    Publisher Universidad Nacional Mayor de San Marcos
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Statins

    Carlo Briguori / Germano Di Sciascio / Enrique C. Morales-Villegas

    International Journal of Hypertension, Vol

    Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins

    2011  Volume 2011

    Keywords Diseases of the circulatory (Cardiovascular) system ; RC666-701 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Cardiovascular ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2011-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Design, Synthesis and Preclinical Assessment of

    Trujillo-Benítez, Diana / Luna-Gutiérrez, Myrna / Ferro-Flores, Guillermina / Ocampo-García, Blanca / Santos-Cuevas, Clara / Bravo-Villegas, Gerardo / Morales-Ávila, Enrique / Cruz-Nova, Pedro / Díaz-Nieto, Lorenza / García-Quiroz, Janice / Azorín-Vega, Erika / Rosato, Antonio / Meléndez-Alafort, Laura

    Molecules (Basel, Switzerland)

    2022  Volume 27, Issue 1

    Abstract: Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tumors. ...

    Abstract Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tumors.
    MeSH term(s) Animals ; Endopeptidases/metabolism ; Hep G2 Cells ; Humans ; Liver Neoplasms, Experimental/diagnostic imaging ; Liver Neoplasms, Experimental/metabolism ; Male ; Membrane Proteins/metabolism ; Mice ; Mice, Inbred BALB C ; Neoplasm Proteins/metabolism ; Organotechnetium Compounds/chemistry ; Organotechnetium Compounds/pharmacokinetics ; Organotechnetium Compounds/pharmacology ; Radiopharmaceuticals/chemistry ; Radiopharmaceuticals/pharmacokinetics ; Radiopharmaceuticals/pharmacology ; Single Photon Emission Computed Tomography Computed Tomography ; Technetium/chemistry ; Technetium/pharmacokinetics ; Technetium/pharmacology
    Chemical Substances Membrane Proteins ; Neoplasm Proteins ; Organotechnetium Compounds ; Radiopharmaceuticals ; Technetium (7440-26-8) ; Endopeptidases (EC 3.4.-) ; fibroblast activation protein alpha (EC 3.4.21.-)
    Language English
    Publishing date 2022-01-01
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules27010264
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: 68

    Trujillo-Benítez, Diana / Luna-Gutiérrez, Myrna / Aguirre-De Paz, José G / Cruz-Nova, Pedro / Bravo-Villegas, Gerardo / Vargas-Ahumada, Joel E / Vallejo-Armenta, Paola / Morales-Avila, Enrique / Jiménez-Mancilla, Nallely / Oros-Pantoja, Rigoberto / Santos-Cuevas, Clara / Azorín-Vega, Erika / Ocampo-García, Blanca / Ferro-Flores, Guillermina

    Pharmaceutics

    2024  Volume 16, Issue 4

    Abstract: Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on ... ...

    Abstract Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the
    Language English
    Publishing date 2024-04-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics16040532
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

    Aroda, Vanita R / Rosenstock, Julio / Terauchi, Yasuo / Altuntas, Yuksel / Lalic, Nebojsa M / Morales Villegas, Enrique C / Jeppesen, Ole K / Christiansen, Erik / Hertz, Christin L / Haluzík, Martin

    Diabetes care

    2019  Volume 42, Issue 9, Page(s) 1724–1732

    Abstract: Objective: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands ... ...

    Abstract Objective: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients.
    Research design and methods: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA
    Results: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA
    Conclusions: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA
    MeSH term(s) Administration, Oral ; Adult ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Diet ; Double-Blind Method ; Exercise ; Female ; Glucagon-Like Peptides/administration & dosage ; Glycated Hemoglobin A/drug effects ; Humans ; Hypoglycemic Agents/administration & dosage ; Male ; Middle Aged ; Weight Loss/drug effects
    Chemical Substances Glycated Hemoglobin A ; Hypoglycemic Agents ; hemoglobin A1c protein, human ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8)
    Language English
    Publishing date 2019-06-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc19-0749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Case Report: Extrapulmonary Manifestations of COVID-19 and Dengue Coinfection.

    Reyes-Ruiz, José Manuel / Campuzano-Vences, Rosa / Osuna-Ramos, Juan Fidel / De Jesús-González, Luis Adrián / Pérez-Méndez, María J / González-González, Crescencio / Farfan-Morales, Carlos Noe / Rivas-Tovar, Leticia / Dávila-González, Eduardo / María Del Ángel, Rosa / Gutiérrez-Garduño, Aarón P / Villegas-Del Ángel, Enrique / Zárate-Segura, Paola / Bastida-González, Fernando

    The American journal of tropical medicine and hygiene

    2021  Volume 105, Issue 2, Page(s) 363–367

    Abstract: The risk of coronavirus disease 2019 (COVID-19) and dengue coinfection is increased in tropical countries; however, the extrapulmonary clinical manifestations have not been fully characterized. We report a 42-year-old woman whose clinical manifestations ... ...

    Abstract The risk of coronavirus disease 2019 (COVID-19) and dengue coinfection is increased in tropical countries; however, the extrapulmonary clinical manifestations have not been fully characterized. We report a 42-year-old woman whose clinical manifestations began with fever, diarrhea, headache, chest pain, myalgia, odynophagia, and arthralgia. Despite mild respiratory symptoms and normal chest computed tomography scan results, she was diagnosed with real-time reverse-transcription polymerase chain reaction (RT-PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Because she had erythema and petechiae with a decreased platelet count, the dengue NS1 antigen and anti-dengue IgM/IgG test were performed, and the Centers for Disease Control and Prevention RT-PCR assay detected the dengue virus serotype 1 infection. Additionally, increased liver enzyme serum levels were found in the patient, who later developed hepatomegaly. Hence, the mechanism of hepatic pathology associated with SARS-CoV-2 and dengue coinfection needs further research.
    MeSH term(s) Adult ; COVID-19/complications ; COVID-19/diagnosis ; Coinfection/complications ; Coinfection/diagnosis ; Coinfection/virology ; Dengue/complications ; Dengue/diagnosis ; Female ; Fever ; Hematology/methods ; Humans ; Lost to Follow-Up ; SARS-CoV-2/classification ; SARS-CoV-2/genetics ; Serogroup ; Thorax/diagnostic imaging ; Tomography, X-Ray Computed
    Language English
    Publishing date 2021-06-28
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2942-7
    ISSN 1476-1645 ; 0002-9637
    ISSN (online) 1476-1645
    ISSN 0002-9637
    DOI 10.4269/ajtmh.21-0177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Identification and Characterization of Novel Fusion Genes with Potential Clinical Applications in Mexican Children with Acute Lymphoblastic Leukemia.

    Mata-Rocha, Minerva / Rangel-López, Angelica / Jiménez-Hernández, Elva / Morales-Castillo, Blanca Angélica / González-Torres, Carolina / Gaytan-Cervantes, Javier / Álvarez-Olmos, Enrique / Núñez-Enríquez, Juan Carlos / Fajardo-Gutiérrez, Arturo / Martín-Trejo, Jorge Alfonso / Solís-Labastida, Karina Anastacia / Medina-Sansón, Aurora / Flores-Lujano, Janet / Sepúlveda-Robles, Omar Alejandro / Peñaloza-González, José Gabriel / Espinoza-Hernández, Laura Eugenia / Núñez-Villegas, Nora Nancy / Espinosa-Elizondo, Rosa Martha / Cortés-Herrera, Beatriz /
    Torres-Nava, José Refugio / Flores-Villegas, Luz Victoria / Merino-Pasaye, Laura Elizabeth / Bekker-Méndez, Vilma Carolina / Velázquez-Aviña, Martha Margarita / Pérez-Saldívar, María Luisa / Bautista-Martínez, Benito Alejandro / Amador-Sánchez, Raquel / González-Avila, Ana Itamar / Jiménez-Morales, Silvia / Duarte-Rodríguez, David Aldebarán / Santillán-Juárez, Jessica Denisse / García-Velázquez, Alejandra Jimena / Rosas-Vargas, Haydeé / Mejía-Aranguré, Juan Manuel

    International journal of molecular sciences

    2019  Volume 20, Issue 10

    Abstract: Acute lymphoblastic leukemia is the most common type of childhood cancer worldwide. Mexico City has one of the highest incidences and mortality rates of this cancer. It has previously been recognized that chromosomal translocations are important in ... ...

    Abstract Acute lymphoblastic leukemia is the most common type of childhood cancer worldwide. Mexico City has one of the highest incidences and mortality rates of this cancer. It has previously been recognized that chromosomal translocations are important in cancer etiology. Specific fusion genes have been considered as important treatment targets in childhood acute lymphoblastic leukemia (ALL). The present research aimed at the identification and characterization of novel fusion genes with potential clinical implications in Mexican children with acute lymphoblastic leukemia. The RNA-sequencing approach was used. Four fusion genes not previously reported were identified:
    MeSH term(s) Adolescent ; Adult ; CREB-Binding Protein/genetics ; Child ; Child, Preschool ; Dyneins/genetics ; Female ; GTPase-Activating Proteins/genetics ; Gene Expression Regulation, Neoplastic ; Gene Rearrangement ; Humans ; Ikaros Transcription Factor/genetics ; Infant ; Male ; Mexico ; Nuclear Proteins/genetics ; Oncogene Proteins, Fusion/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Prognosis ; Proto-Oncogene Proteins c-ets/genetics ; RNA Cap-Binding Proteins/genetics ; RNA-Binding Proteins/genetics ; Receptors, Cytoplasmic and Nuclear/genetics ; Repressor Proteins/genetics ; Translocation, Genetic/genetics ; Young Adult ; ETS Translocation Variant 6 Protein
    Chemical Substances GTPase-Activating Proteins ; IKZF1 protein, human ; NUFIP1 protein, human ; Nuclear Proteins ; Oncogene Proteins, Fusion ; Proto-Oncogene Proteins c-ets ; RNA Cap-Binding Proteins ; RNA-Binding Proteins ; Receptors, Cytoplasmic and Nuclear ; Repressor Proteins ; SNUPN protein, human ; SRGAP3 protein, human ; Ikaros Transcription Factor (148971-36-2) ; CREB-Binding Protein (EC 2.3.1.48) ; CREBBP protein, human (EC 2.3.1.48) ; DNAH14 protein, human (EC 3.6.4.2) ; Dyneins (EC 3.6.4.2)
    Language English
    Publishing date 2019-05-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms20102394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top